Fib resistance + RSI bullish reversal After the bearish news earlier today, it seems like Novo has had its final capitulation.
There's a fib resistance + historical resistance dating back to '21-'22.
On the weekly, the RSI is also presenting a bullish divergence - although we may want to await the closing of this week to confirm this.
T
Key facts today
Barclays downgraded Novo Nordisk (NOVO_B) from overweight to equal-weight and reduced its target price from DKK 700 to DKK 375.
Jefferies analysts warned that a profit alert could impact views on the obesity market, while Novo Nordisk reported slow growth for its Wegovy and Ozempic drugs in the U.S.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.013 CHF
12.69 B CHF
36.50 B CHF
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG006M6YKB4
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
$NVO Accumulating long term compounder! - Previously, I have shorted NYSE:NVO when it was in $75-85 when moat was weakening and then went long around $58 to $75 for 40% on the long side. Everything is documented in my two posts.
- People are asking me if NYSE:NVO is cheap or not. After cutting guidance, I believe most of the estimat
Is Novo Nordisk a buy? Novo Nordisk $NYSE: NVO plummets 22% on July 29, wiping out $57.5B in market value!
Here's what's happening and how I see it.
Here’s the breakdown on why the stock hit its lowest since Nov 2022:
Slashed 2025 Guidance: Sales growth cut to 8–14% from 13–21%, operating profit to 10–16% from 16–2
NVO Could Bounce Back Soon ?!NVO dropped hard (over 20%) mainly because of a legal issue. I think this is temporary and will get solved with time. The stock is now super oversold and sitting on strong support around $52–53.
• Entry: $52–54
• Target 1: $56.90
• Target 2: $66.40
• Stop Loss: $50
If the issue clears, we could
$NVO offers solid risk to reward for long term buyers! - I had previously called out that NYSE:NVO would have more pain to come when it was in $85-90s I have attached the link with this post for my reader's reference.
- Now, I am turning bullish on this name given these prices and compressed multiples for the growth prospects it offers.
Fundamenta
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOV is featured.
Frequently Asked Questions
The current price of NOV is 40.899 CHF — it has decreased by −23.16% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange NOVO NORDISK A/S stocks are traded under the ticker NOV.
NOV stock has fallen by −16.53% compared to the previous week, the month change is a −20.32% fall, over the last year NOVO NORDISK A/S has showed a −64.41% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOV price has a max estimate of 93.45 CHF and a min estimate of 37.38 CHF. Watch NOV chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOV stock is 8.20% volatile and has beta coefficient of 1.44. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 191.97 B, it has decreased by −5.10% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.84 CHF per share, whereas the estimation was 0.78 CHF resulting in a 6.95% surprise. The estimated earnings for the next quarter are 0.74 CHF per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 10.02 B CHF, despite the estimated figure of 10.00 B CHF. In the next quarter, revenue is expected to reach 9.59 B CHF.
NOV net income for the last quarter is 3.72 B CHF, while the quarter before that showed 3.55 B CHF of net income which accounts for 4.95% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jul 30, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 20.12 B CHF, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.